BioCentury | Apr 14, 2021
Finance

Tango & Cash: the latest in string of biotech SPAC mergers: Data Byte

Tango and Surrozen completed SPAC deals this week to bring the total number of biotech SPAC mergers to at least 22. Tango Therapeutics Inc., a synthetic lethality company, said on Wednesday it is merging with BCTG Acquisition...
BioCentury | Apr 7, 2021
Distillery Therapeutics

RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of membrane-tethered...
BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

...of Arthrex, the remedy may be to delete...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

Two papers characterizing cases of resistance to bluebird and BMS’s multiple myeloma CAR T cell therapy point to a vulnerability that could extend to other anti-BCMA therapies — loss of the target’s gene....
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 11, 2021
Politics, Policy & Law

Cancer KOLs urge Biden to name Woodcock permanent FDA commissioner

...has picked up a powerful endorsement in a public campaign for President Joe Biden to delete...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

After giving up rights to CRISPR-Cas9 for most therapeutic applications years ago, Jennifer Doudna-founded Caribou is now teaming up with AbbVie to use a different CRISPR enzyme to create allogeneic CAR...
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

Dyne’s myotonic dystrophy antisense therapy reduces gene expressionDyne Therapeutics Inc. (NASDAQ:DYN) reported data from a new mouse model of severe disease showing its myotonic dystrophy type 1 (DM1) antisense oligonucleotide therapy reduced nuclear DMPK RNA levels...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting vesicular trafficking protein SURF4 to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Targeting the ER cargo receptor SURF4 could treat atherosclerosis and dyslipidemia. In a mouse model of atherosclerosis, liver-specific heterozygous or homozygous SURF4 deletion reduced cholesterol and triglyceride levels in plasma...
Items per page:
1 - 10 of 1408
BioCentury | Apr 14, 2021
Finance

Tango & Cash: the latest in string of biotech SPAC mergers: Data Byte

Tango and Surrozen completed SPAC deals this week to bring the total number of biotech SPAC mergers to at least 22. Tango Therapeutics Inc., a synthetic lethality company, said on Wednesday it is merging with BCTG Acquisition...
BioCentury | Apr 7, 2021
Distillery Therapeutics

RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of membrane-tethered...
BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

...of Arthrex, the remedy may be to delete...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 24, 2021
Product Development

Evidence mounts that BCMA CAR T cells are vulnerable to antigen escape

Two papers characterizing cases of resistance to bluebird and BMS’s multiple myeloma CAR T cell therapy point to a vulnerability that could extend to other anti-BCMA therapies — loss of the target’s gene....
BioCentury | Feb 12, 2021
Product Development

How COVID-19 drug developers can stay ahead of viral variants

With a combination of genomic surveillance and in vitro laboratory assays, COVID-19 drug developers have the tools to get an early read on the vulnerability of their candidates to viral variants and course...
BioCentury | Feb 11, 2021
Politics, Policy & Law

Cancer KOLs urge Biden to name Woodcock permanent FDA commissioner

...has picked up a powerful endorsement in a public campaign for President Joe Biden to delete...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

After giving up rights to CRISPR-Cas9 for most therapeutic applications years ago, Jennifer Doudna-founded Caribou is now teaming up with AbbVie to use a different CRISPR enzyme to create allogeneic CAR...
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

Dyne’s myotonic dystrophy antisense therapy reduces gene expressionDyne Therapeutics Inc. (NASDAQ:DYN) reported data from a new mouse model of severe disease showing its myotonic dystrophy type 1 (DM1) antisense oligonucleotide therapy reduced nuclear DMPK RNA levels...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting vesicular trafficking protein SURF4 to treat atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Targeting the ER cargo receptor SURF4 could treat atherosclerosis and dyslipidemia. In a mouse model of atherosclerosis, liver-specific heterozygous or homozygous SURF4 deletion reduced cholesterol and triglyceride levels in plasma...
Items per page:
1 - 10 of 1408